Li N
Department of Colorectal Disease Specialty, Intestinal Microecology Diagnosis and Treatment Center, the Tenth People's Hospital, Tongji University, Shanghai 200072, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Jul 10;23(Z1):1-4. doi: 10.3760/cma.j.cn.441530-20200420-00230.
As an innovative therapy, FMT has made a breakthrough in the treatment of recurrent infection (CDI). With the rapid development of biotechnology, the relationship between intestinal microflora and diseases has been gradually eluciated. Great hope has also been given to FMT in other intestinal and extraintestinal diseases with ineffective traditional treatment. However, as a new therapy method, FMT still has many unknown fields, such as the selection of clinical donors, the preparation of standardized bacterial solution and capsule, the selection of indications, the matching of donor and receptor, and the prevention and treatment of complications. Since 2012, our center has carried out treatment research and practice of FMT, so far with more than 60 000 FMTs for more than 3500 cases. Based on large sample data and experience, this special issue reports and discusses the above topics, and focuses on the establishment and clinical application of standardized methodology of FMT, which will undoubtedly play a positive role in promoting the healthy development of FMT treatment in China.
作为一种创新疗法，粪菌移植（FMT）在复发性感染（CDI）的治疗方面取得了突破。随着生物技术的快速发展，肠道微生物群与疾病之间的关系已逐渐被阐明。对于传统治疗无效的其他肠道和肠外疾病，粪菌移植也带来了巨大希望。然而，作为一种新的治疗方法，粪菌移植仍有许多未知领域，如临床供体的选择、标准化菌液和胶囊的制备、适应证的选择、供体与受体的匹配以及并发症的防治等。自2012年以来，我们中心开展了粪菌移植的治疗研究与实践，迄今为止已为3500余例患者进行了60000余次粪菌移植。基于大样本数据和经验，本期专题报道并讨论上述主题，重点关注粪菌移植标准化方法的建立及临床应用，这无疑将对推动我国粪菌移植治疗的健康发展起到积极作用。
